Modulation of thrombin's procoagulant and anticoagulant properties
- PMID: 9198219
Modulation of thrombin's procoagulant and anticoagulant properties
Abstract
The procoagulant and anticoagulant functions of thrombin are controlled physiologically by allosteric changes induced by Na+ and vascular cell-surface TM. Key residues that mediate Na+ interaction with thrombin have been identified. Based on a site-directed mutagenesis approach, E229K thrombin is found to be the most optimal and potent PC activator with a marked shift in substrate specificity for PC over fibrinogen. E229K thrombin demonstrates significant anticoagulant and antithrombotic efficacy in animal models in vivo. Alternatively, a synthetic organic molecule (LY254603) has been discovered which interacts with thrombin and effectively modulates its functions in vitro. This new class of antithrombotic agents exploits the powerful natural PC anticoagulant pathway and may have a superior therapeutic profile than direct thrombin inhibitors.
Similar articles
-
Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo.Biochemistry. 1996 Dec 24;35(51):16449-57. doi: 10.1021/bi9616108. Biochemistry. 1996. PMID: 8987977
-
Conversion of thrombin into an anticoagulant by protein engineering.Nature. 1995 Nov 23;378(6555):413-6. doi: 10.1038/378413a0. Nature. 1995. PMID: 7477382
-
Dissociation of thrombin's substrate interactions using site-directed mutagenesis.Trends Cardiovasc Med. 2000 Feb;10(2):89-92. doi: 10.1016/s1050-1738(00)00047-5. Trends Cardiovasc Med. 2000. PMID: 11150736 Review.
-
Rational engineering of activity and specificity in a serine protease.Nat Biotechnol. 1997 Feb;15(2):146-9. doi: 10.1038/nbt0297-146. Nat Biotechnol. 1997. PMID: 9035139
-
Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties.Cell Mol Life Sci. 1997 Sep;53(9):731-6. doi: 10.1007/s000180050092. Cell Mol Life Sci. 1997. PMID: 9368669 Free PMC article. Review.
Cited by
-
New anticoagulant drugs.J Thromb Thrombolysis. 2001 Sep;12(1):7-17. doi: 10.1023/a:1013089924994. J Thromb Thrombolysis. 2001. PMID: 11711683 Review.
-
Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands.Int J Mol Sci. 2021 Oct 6;22(19):10803. doi: 10.3390/ijms221910803. Int J Mol Sci. 2021. PMID: 34639143 Free PMC article. Review.
-
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).Mol Immunol. 2008 Oct;45(16):4080-3. doi: 10.1016/j.molimm.2008.07.010. Epub 2008 Aug 15. Mol Immunol. 2008. PMID: 18706698 Free PMC article. Review.
-
Hageman factor, platelets and polyphosphates: early history and recent connection.J Thromb Haemost. 2010 Aug;8(8):1670-4. doi: 10.1111/j.1538-7836.2010.03893.x. Epub 2010 Apr 30. J Thromb Haemost. 2010. PMID: 20456750 Free PMC article. Review.
-
Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo.Blood. 2007 Mar 1;109(5):1992-7. doi: 10.1182/blood-2006-03-012567. Epub 2006 Nov 14. Blood. 2007. PMID: 17105819 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical